Recent data from more than 15,000 patients with type 2 diabetes show that initial therapy with Avandia was associated with significantly lower medical costs and total visits to the doctor compared to patients who were treated with a sulfonylurea. Dr. Mel Sheng Duh, the co-author of the study, said, "the study findings demonstrate that treatment with Avandia resulted in significantly lower total medical costs for the patient over time, when compared to sulfonylurea therapy. These data are important to physicians selecting treatment for their patients because the financial burden of diabetes and its associated health problems is staggering -- not only to patients but to their families and the healthcare system as well."

New Data Show Patients Treated With Avandia(R) (Rosiglitazone Maleate) Incurred Lower Medical Costs and Used Fewer Healthcare Resources When Compared to Patients Treated With Sulphonylureas